



New automation technologies at the vanguard of IFA diagnostics

EUROIMMUN has been creating innovative solutions for immunofluorescence diagnostics for over thirty years. Continuing this long tradition, the company has over the last year introduced further groundbreaking products to increase the efficiency and standardization of indirect immunofluorescence assay (IFA) analyses. CLI talked to *Dr Panagiotis Grypiotis, Head of Product Management Autoimmune Diagnostics, Endocrinology/Biologics and Automation & Software* at EUROIMMUN to learn how the new technologies can transform IFA analyses in the laboratory.

Why are indirect immunofluorescence assays (IFAs) so central for diagnostics?

IFAs count among the fundamental screening methods for the detection of anti-bodies, for example in autoimmune or infectious diseases. Owing to the growing life expectancy and burgeoning population of chronically ill individuals, the global demand for IFA diagnostics is continually increasing.

What are the challenges for laboratories?

Although demand for IFAs is increasing, there is a general lack of skilled staff to perform and evaluate the analyses. Some laboratories are merging to overcome this bottleneck. To manage high sample volumes, labs also require high-performance automation systems to minimize the manual workload and deliver highly standardized results.

